吡格列酮
医学
内科学
入射(几何)
糖尿病
危险系数
置信区间
噻唑烷二酮
比例危险模型
2型糖尿病
内分泌学
光学
物理
作者
Yu‐Hung Chang,Shih‐Jung Yen,Yo-Chen Chang,Wen‐Jeng Wu,Kun‐Der Lin
摘要
Background and purpose The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear. No study has examined the interaction between pioglitazone and statin treatment on prevention of PD. This study analyzed the associations between pioglitazone, statins, and the incidence of PD in patients with diabetes mellitus (DM) in Taiwan. Methods We used the National Health Insurance database from 1996 to 2013. DM and PD were diagnosed according to the International Classification of Diseases , Ninth Revision , Clinical Modification codes. We used the propensity score‐matching method to match the study groups. Cox regression analyses were employed to calculate the relative risk of the incidence of PD. Results There were 48 828 patients matched and categorized equally into the pioglitazone group and the non‐pioglitazone group. The number of PD patients in the pioglitazone group and the non‐pioglitazone group was 275 (1.1%) and 417 (1.7%), respectively. The pioglitazone group had a lower incidence of PD, with an adjusted hazard ratio (aHR) of 0.66 [95% confidence interval (CI): 0.57–0.78], and this benefit was dose‐dependent. Of note, as compared with either pioglitazone or statin treatment, our results first showed that the combination of pioglitazone and statins further lowered the risk of PD, with an aHR of 0.78 (95% CI: 0.64–0.94; P = 0.010). Conclusions Our study results suggested that pioglitazone could be a promising agent for reducing the incidence of PD in patients with DM, and works synergistically with statins.
科研通智能强力驱动
Strongly Powered by AbleSci AI